Clot removal device test for acute pulmonary embolism
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial studies a clot-removal device used through a catheter to treat acute pulmonary embolism (a blood clot in the lungs). It aims to see if the device can safely remove clots and improve outcomes compared with standard care planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- Your symptoms and scan fit an acute pulmonary embolism (clot in the lung) and started within the last 14 days
- A CT scan shows a clot in a main or lobar lung artery, and your heart strain measurement is high enough (RV/LV ratio at least 0.9 by the investigator’s reading)
- Your blood pressure is at least 90 (top number), and your heart rate is under 130 before the procedure
- Your oxygen needs are not too high (you likely can’t need more than 40% oxygen or more than 6 liters/min to keep oxygen saturation over 90%)
- There are no major safety blockers (recent clot-related treatments, severe kidney/liver/blood-count problems, high bleeding risk, certain heart/lung conditions, or pregnancy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new device (AlphaVac) that removes blood clots from the lungs using a thin tube inserted through a vein. It may be an option for people with acute pulmonary embolism who have signs of heart strain or low blood pressure.
This Phase 3 trial tests a catheter-based procedure to remove a lung blood clot (pulmonary embolism) and reduce strain on the heart. It may help people who have specific CT scan signs of right-heart strain.
This trial tests a new treatment for people with a severe, high-risk pulmonary embolism (blood clot in the lung). It uses a catheter device to remove the clot and help the heart work better.
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
This trial compares three treatments for an intermediate-high risk pulmonary embolism: a minimally invasive clot removal procedure (embolectomy), a low-dose clot-dissolving medication, or standard blood thinning (heparin). The goal is to see which approach works best to prevent worsening while reducing bleeding risks.
This study tests a new way of delivering a clot-dissolving medicine for people with a serious but not immediately life-threatening pulmonary embolism. The goal is to see if giving the medicine as small bursts directly into the clot can help the heart recover faster.
Hear when a new Pulmonary Embolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.